Table 2.
Demographic and Psychiatric Characteristics
| Characteristic | Total (N=100) | Explained (N=48) | Unexplained (N=52) | P Value |
|---|---|---|---|---|
| Age (years ± SD) | 49.4 ± 12.1 | 49.0 ± 12.7 | 49.7 ± 13.0 | NS |
| Sex | ||||
| Male (%) | 62 (62.0) | 31 (64.6) | 31 (59.6) | NS |
| Female (%) | 38 (38.0) | 17 (35.4) | 21 (40.4) | NS |
| Primary Psychiatric Diagnosesa | ||||
| Psychotic Disorders (%) | 33 (34.0) | 17( 37.8) | 16 (30.8) | NS |
| Schizophrenia (%) | 27 (27.8) | 14 (31.1) | 13 (25.0) | NS |
| Psychosis NOSb (%) | 6 (6.2) | 3 (6.3) | 3 (5.8) | NS |
| Mood Disorders (%) | 46 (47.4) | 21 (36.6) | 25 (48.1) | NS |
| Bipolar Disorder (%) | 18 (18.6) | 10 (22.2) | 8 (15.4) | NS |
| Major Depression (%) | 19 (19.6) | 5 (11,1) | 14 (26.9) | NS |
| Depression NOSb (%) | 9 (9.3) | 6 (13.3) | 3 (5.8) | NS |
| Anxiety Disorders (%) | 5 (5.2) | 3 (6.3) | 2 (3.8) | NS |
| Substance Use Disorders (%) | 9 (9.3) | 2 (4.4) | 7 (13.5) | NS |
| Other (%) | 4 (4.1) | 2 (4.4) | 2 (3.8) | NS |
| Psychotropic Treatment | ||||
| First Generation Antipsychotics (%) | 9 (9.0) | 5 (10.4) | 4 (7.7) | NS |
| Second Generation Antipsychotics (%) | 40 (41.0) | 17 (35.4) | 23 (44.2) | NS |
| Clozapine (%) | 9 (9.0) | 4 (8.3) | 5 (9.6) | NS |
| Olanzapine (%) | 8 (8.0) | 6 (12.5) | 2 (3.8) | NS |
| Quetiapine (%) | 11 (11.0) | 0 (0.0) | 11 (21.2) | 0.002 |
| Risperidone (%) | 9 (9.0) | 5 (10.4) | 4 (7.7) | NS |
| Aripiprazole (%) | 2 (2.0) | 2 (4.2) | 0 (0.0) | NS |
| Ziprasidone (%) | 1 (1.0) | 0 (0.0) | 1 (1.9) | NS |
| Antidepressants (%) | 33 (33.0) | 13 (27.1) | 20 (38.5) | NS |
| SSRIc (%) | 19 (19.0) | 8 (16.7) | 11 (21.2) | NS |
| SNRId (%) | 11 (11.0) | 1 (3.1) | 10 (19.2) | 0.012 |
| Tricyclics | 5 (5.0) | 2 (4.2) | 3 (5.8) | NS |
| Mirtazapine (%) | 5 (5.0)) | 1 (3.1) | 4 (7.7) | NS |
| Mood Stabilizers (%) | 16 (16.0) | 7 (14.6) | 9 (17.3) | NS |
| Lithium (%) | 6 (6.0) | 4 (8.3) | 2 (3.8) | NS |
| Valproate (%) | 6 (6.0) | 3 (6.3) | 3 (5.8) | NS |
| Gabapentine (%) | 4 (4.0) | 0 (0.0) | 4 (7.7) | NS |
| Lamotrigine (%) | 3 (3.0) | 0 (0.0) | 3 (5.8) | NS |
| Benzodiazepines (%) | 9 (9.0) | 3 (6.3) | 6 (11.6) | NS |
| Methadone (%) | 2 (2.0) | 0 (0.0) | 2 (3.8) | NS |
| Psychostimulants (%) | 3 (3.0) | 1 (3.1) | 2 (3.8) | NS |
a
=Diagnostic data missing for 3 patients from the Explained group;
b
=Not otherwise specified;
c
=selective serotonin reuptake inhibitors;
d
=serotonin-norepinephrine reuptake inhibitors